Retatrutide Halves Knee Arthritis Pain in Two Major Trials as Weight Loss Nears 29%

Retatrutide, Eli Lilly's experimental weight-loss drug, cut knee osteoarthritis pain in half in two major phase 3 trials, with patients losing up to 28.7% of their body weight, results published in the New England Journal of Medicine show. The findings, presented at the American College of Rheumatology Convergence 2026 in Orlando, are the first large-scale evidence that a weight-loss medicine can bring major relief for worn-out knees, a leading cause of disability in the US.

Key Points

• Two phase 3 trials of once-weekly retatrutide, published in the New England Journal of Medicine on November 8, 2026, show it significantly eases knee osteoarthritis pain in adults with obesity.
• In TRIUMPH-4, pain fell 3.96 points on 9 mg and 3.74 on 12 mg, versus 2.12 on placebo, with weight loss of 20.0% and 23.7%, up to 28.7%.
• In TRIUMPH-1-OA, pain fell 3.22 to 3.64 points, versus 1.87 on placebo, with weight loss of 17.5% to 24.8%.
• About two-thirds on retatrutide had at least 50% less knee pain, versus 38% on placebo; over one in eight in TRIUMPH-4 ended pain-free.
• Retatrutide is not yet approved by the US Food and Drug Administration; Eli Lilly plans to seek approval in the first quarter of 2027.

What Happened

On Sunday, November 8, 2026, researchers published results from two late-stage trials testing whether retatrutide, a once-weekly injection known for dramatic weight loss, could also relieve knee osteoarthritis pain. TRIUMPH-4 and TRIUMPH-1-OA enrolled just over 1,000 adults with obesity and knee osteoarthritis without type 2 diabetes; both were funded by Eli Lilly.

In TRIUMPH-4 (68 weeks, 445 adults), WOMAC pain scores fell 3.96 points on 9 mg and 3.74 on 12 mg, against 2.12 on placebo, while patients lost 20.0% and 23.7% of body weight, versus 4.6%. In TRIUMPH-1-OA, 574 adults on 4, 9 or 12 mg saw pain fall 3.22, 3.48 and 3.64 points over 80 weeks, versus 1.87 on placebo, with weight loss of 17.5% to 24.8%. Across both trials, about two-thirds on retatrutide had their knee pain cut by at least half, versus 38% on placebo.

Most striking of all, more than one in eight patients in TRIUMPH-4 finished the trial reporting no knee pain at all — unusual for a condition that usually worsens year after year and often ends in joint replacement surgery.

Background: Why Weight and Knees Are So Closely Linked

In knee osteoarthritis, the cartilage cushioning the joint wears away, causing pain, swelling, stiffness and impaired movement. The World Health Organization lists older age, joint injury and overweight or obesity as the major risk factors, and studies suggest two-thirds of people with obesity have knee osteoarthritis.

Weight loss is one of the few treatments that addresses a cause of the disease, not just its symptoms, cutting the load on the knee and easing the low-grade inflammation excess fat tissue produces. Retatrutide belongs to the new generation of weight-loss medicines that began with semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), but goes further as a triple agonist on the GLP-1, GIP and glucagon receptors, cutting appetite and changing how the body handles energy.

Retatrutide Knee Arthritis Pain: What the Trials Actually Show

The trials were built around the WOMAC pain score, a 0-to-10 scale on which lower is better, and change in body weight. In both studies the drug beat placebo on pain by a wide margin, and the benefit grew with the weight loss — a pattern that held across doses and trial lengths.

Still, the details matter. The trials excluded people who already needed a knee replacement, so they say nothing about the most advanced cases, and were not designed to show whether retatrutide slows damage to the joint itself. Every pound of body weight means roughly two to five pounds of force across the knee, so a 20% weight loss cuts the load sharply — but whether the drug changes the disease's course remains open.

Reactions and Quotes

Orthopaedic surgeon Dr Timothy Gibson, who was not involved in the study, welcomed the findings. "This study reinforces something orthopedic surgeons have recognized for years: weight management is an important component of treating knee osteoarthritis, particularly in patients who have obesity or overweight," he told Medical News Today.

"For some patients, that could mean walking more comfortably, returning to activities they enjoy, or delaying the need for knee replacement," Gibson added. But he urged caution: "Retatrutide is not an anti-inflammatory medication administered into the joint, and we do not yet have convincing clinical evidence that it directly repairs cartilage, reverses arthritis, or changes the structural progression of osteoarthritis." He called for longer studies on whether the gains last and whether the drug cuts the need for knee replacement surgery.

Sebnem Unluisler of the London Regenerative Institute, also not involved in the study, agreed the drug's combined action could offer extra metabolic and anti-inflammatory benefits, "although a direct effect on joint inflammation remains unproven."

Why It Matters

Knee osteoarthritis affects tens of millions of Americans, and its burden grows as the population ages and obesity rates rise. Existing treatments are limited: painkillers, physiotherapy, injections and, eventually, surgery. A medicine that tackles the weight driving the disease could change how the condition is treated — and a proven benefit for knee pain would give retatrutide, already one of the most closely watched medicines in development, a use beyond obesity.

What Happens Next

Eli Lilly plans to apply to the US Food and Drug Administration for approval in the first quarter of 2027. Researchers also want longer follow-up: does pain relief last once patients stop the drug, does it slow joint damage or cut the need for knee replacement, and does it help people without obesity? Doctors say the drug, if approved, would be one tool among several — exercise, low-impact activity, good nutrition and protecting muscle mass remain part of the plan, and no medicine yet repairs worn cartilage.

Frequently Asked Questions

What is retatrutide?
Retatrutide is an experimental once-weekly injectable from Eli Lilly that acts on the GLP-1, GIP and glucagon receptors to cut appetite. It is not yet approved by the US Food and Drug Administration.

How much did retatrutide reduce knee pain?
In TRIUMPH-4, pain fell 3.96 points on 9 mg and 3.74 on 12 mg, versus 2.12 on placebo; in TRIUMPH-1-OA it fell 3.22 to 3.64 points, versus 1.87. About two-thirds had their pain cut by at least half.

How much weight did patients lose?
Patients lost 20.0% to 23.7% of body weight in TRIUMPH-4, up to 28.7%, and 17.5% to 24.8% in TRIUMPH-1-OA, versus about 4% on placebo.

When could retatrutide be approved?
Eli Lilly plans to apply for US approval in the first quarter of 2027; approval would depend on the regulator's review of the trial results and safety data.

Does retatrutide cure knee osteoarthritis?
No. There is no evidence yet that it repairs cartilage or reverses joint damage. It relieves pain, largely through major weight loss, and should be used with exercise, nutrition and muscle-preserving care.

Read more on health: Foundayo pill cuts sleep apnoea episodes 44% in Lilly trials and FDA approves Sunharbo to cut repeat stroke risk 26%.